SETLAKIN Drug Patent Profile
✉ Email this page to a colleague
When do Setlakin patents expire, and when can generic versions of Setlakin launch?
Setlakin is a drug marketed by Novast Labs and is included in one NDA.
The generic ingredient in SETLAKIN is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for SETLAKIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SETLAKIN |
DailyMed Link: | SETLAKIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SETLAKIN
US Patents and Regulatory Information for SETLAKIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novast Labs | SETLAKIN | ethinyl estradiol; levonorgestrel | TABLET;ORAL | 090716-001 | Sep 15, 2014 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |